Melanoma Matters Pod

Melanoma Matters

Health EN ↓ 95 episodes

From the UK to the USA - Melanoma Matters is on a mission! Hosts James Larkin and Sapna Patel are spreading the word on melanoma, one podcast at a time. Tune in for a critical review of the literature and a discussion of how we incorporate the data into our practices...across the pond(s). #MelanomaMatters video podcast

Be sure to visit the podcast's website and support the creator: www.melanomamatters.com

Author

Melanoma Matters Pod

Category

Health

Podcast website

www.melanomamatters.com

Latest episode

Oct 16, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

Ep 20: Neoadjuvant Nivolumab + Relatlimab 14.10.2024

Summary What is the plural of myocarditis? Prof Larkin claims it is myocarditities. In this episode of Melanoma Matters, James Larkin and Sapna Patel discuss the recent study on neoadjuvant therapy using Nivolumab and Relatlimab for melanoma treatment. They explore the study's design, results, and implications for future therapies, particularly focusing on the high rate of complete pathological re...

Ep 19: Single-dose of neoadjuvant pembro (UPenn study) 14.10.2024

Why make the bed? Who needs a mnemonic for washing? In the opening quickfire discussion, James and Sapna get SERIOUS. In this episode, they discuss a paper from Nature Medicine 2019 titled 'Single Dose of Neoadjuvant PD-1 Blockade Predicts Clinical Outcomes in Resectable Melanoma.' They explore the significance of the study, which showed that a single dose of preoperative PD-1 blockade can induce...

Ep 18: SD101 + Pembro 14.10.2024

Summary Sapna reveals her most used emoji is a heart (awww..... <3) and James just avoids the question. Neither has decided on their theme song as a wrestler which means they won't be quitting their day jobs anytime soon. In this episode, James and Sapna discuss the injectable treatment SD101, its mechanism, efficacy in different patient populations, and the challenges faced in its development....

Ep 17: TVEC + Ipi 14.10.2024

Summary This one's for you Dennie Jones (and Alex Nguyen & Shagufta Naqvi)! And the incredible experience they provided one of us as a medical student that shaped a future path. (Honorable mention to GI Fellow at the time Binh Pham and his turtles & friendship.) In this conversation, James Larkin and Sapna Patel discuss the combination of TVEC and IPI in treating melanoma, focusing on rece...

Ep 16: MASTERKEY 265 14.10.2024

Summary James gives a response of plausible deniability that hints at activities as a spy for MI6. But is Sapna perhaps the optimal agent for the clandestine services? In this episode of Melanoma Matters, hosts Sapna Patel and James Larkin discuss the intricacies of the MASTERKEY 265 study, focusing on the combination of TVEC and pembrolizumab in melanoma treatment. They explore the study's de...

Ep 15: OPTiM 14.10.2024

Summary One wonders if Prof Martin Gore ever dreamed he would be mentioned in the same context as HRH and Taylor Swift. If he's listening, he must know which of the goldilocks chairs he occupies. In this episode of Melanoma Matters, hosts Sapna Patel and James Larkin discuss injectable therapies for melanoma, focusing on Talimogene Laherparepvec (TVEC) and the Optim trial. They explore the trial's...

Ep 14: IMMUNED 14.10.2024

Summary In this episode of Melanoma Matters, Sapna Patel and James Larkin discuss the IMMUNED study, a randomized phase 2 trial for resected stage 4 melanoma with no evidence of disease (NED). They explore the study design, efficacy results, and subgroups analysis. They also discuss the use of checkpoint inhibitors in the adjuvant setting and the management of oligometastatic disease. The key take...

Ep 13: SWOG S1801 14.10.2024

Summary In this conversation, James Larkin and Sapna Patel discuss the S1801 study, a neoadjuvant study in melanoma. They talk about the background and design of the study, including the decision to compare neoadjuvant therapy to adjuvant therapy using pembrolizumab. They also discuss the efficacy and toxicity of the neoadjuvant approach, as well as the importance of central pathologic review. The...

Ep 12: PRADO 14.10.2024

Summary In this conversation, James Larkin and Sapna Patel discuss the PRADO study, which focuses on neoadjuvant therapy for melanoma. The study explores the use of personalized response-driven approaches to treatment, based on the patient's response to combination immunotherapy. The study found that patients with a major pathological response had a low rate of recurrence in the first two years, s...

Ep 11: OpACIN-Neo 14.10.2024

Summary In this conversation, James Larkin and Sapna Patel discuss neoadjuvant treatment in melanoma. They start by talking about the best films they've seen in the last five years, then move on to the background and rationale behind neoadjuvant therapy. They discuss the use of BRAF targeted therapy and its limitations, as well as the effectiveness of immunotherapy in the neoadjuvant setting. They...

Ep 10: CheckMate 915 14.10.2024

Summary Birth order and bad second languages and Bolivia. In this episode of Melanoma Matters, hosts Sapna Patel and James Larkin discuss the Checkmate 915 trial, a significant study in the adjuvant treatment of melanoma. They explore the trial's design, the implications of IPI dosing, and the balance between efficacy and toxicity. The conversation emphasizes the importance of understanding negati...

Ep 09: CheckMate 76K 14.10.2024

Summary In this episode of Melanoma Matters, hosts Sapna Patel and James Larkin have a disastrous quickfire discussing their would-be porn star names and eventually move on to the Checkmate 76K study, which evaluates the efficacy of Nivolumab in adjuvant therapy for stage 2 melanoma. They delve into the interpretation of hazard ratios, the choice between Nivolumab and Pembrolizumab, and the manage...

Ep 08: KEYNOTE 716 14.10.2024

Summary In this episode of Melanoma Matters, James Larkin and Sapna Patel discuss the Keynote 716 trial, focusing on the treatment of stage 2 melanoma. They explore the implications of adjuvant therapies, the significance of recurrence-free survival (RFS) and distant metastasis-free survival (DMFS), and the role of BRAF testing in managing stage 2 patients. The conversation highlights the challeng...

Ep 07: KEYNOTE 054 14.10.2024

Summary James is injured! Hear about his favorite style of exercise (strength v cardio), and his no excuses attitude towards aches, pains, and niggles. In this episode, Sapna and James discuss the Keynote 054 study, which examines the efficacy of adjuvant pembrolizumab (Pembro) versus placebo in patients with resected stage 3A to 3C melanoma. They explore the study's design, results, and implicati...

Ep 06: CheckMate 238 14.10.2024

Summary In this conversation, Sapna Patel and James Larkin discuss the Checkmate 238 landmark study on adjuvant therapy for melanoma. They touch on various topics, including food choices, pets, and the study design. They highlight the importance of considering the heterogeneity and tempo of melanoma in treatment decisions. They also discuss the challenges of conducting dedicated trials for mucosal...

Ep 05: SWOG S1404 14.10.2024

In this conversation, James Larkin and Sapna Patel discuss the SWOG adjuvant study in melanoma. They cover topics such as the study design, the use of adjuvant anti-PD-1 therapy, the comparison with interferon and ipilimumab, and the potential side effects of adjuvant treatment. They also touch on the importance of risk-benefit discussions with patients and the need for biomarkers to predict toxic...

Ep 04: EORTC 18071 14.10.2024

In this conversation, Sapna Patel and James Larkin discuss the EORTC 18071 study, which compared adjuvant ipilimumab to placebo in patients with stage III melanoma. They explore the use of adjuvant interferon in the past and the controversies surrounding its overall survival benefit. They also discuss the tolerability and side effects of ipilimumab, as well as the potential reasons for the surviva...

Ep 03: CheckMate-204 14.10.2024

Summary In this conversation, James Larkin and Sapna Patel discuss the findings of the Checkmate 204 study, which looked at the treatment of brain metastases from melanoma using nivolumab and ipilimumab. They highlight that the combination therapy showed efficacy in asymptomatic patients with brain metastases, with a 55% intracranial clinical benefit rate. They also discuss the importance of early...

Ep 02: RELATIVITY-047 14.10.2024

Summary In this episode of Melanoma Matters, James Larkin and Sapna Patel discuss the RELATIVITY 047 trial, which evaluated the combination of nivolumab and relatlimab in frontline metastatic melanoma. They cover the trial design, response rates, overall survival, toxicity, and the role of PD-L1 expression in treatment decisions. They also explore the potential use of nivolumab and relatlimab in p...

Ep 01: CheckMate-067 14.10.2024

In this inaugural episode of Melanoma Matters, hear our what, why, and thank yous. Thank you (luv-u) to our producer big sister (general) Kippy , to David Gedge and The Wedding Present for use of their song "My Favourite Dress," and to the Uromigos duo of Tom & Brian for showing us what is possible. In Episode 01, Sapna Patel and James Larkin discuss the CheckMate 067 study, a randomized phase...

Listen to the Melanoma Matters podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.